SARS-CoV-2-IgG antibodies
Conditions
Interventions
Group 1: Blood is taken once from employees of the ukb to test the antibody response to a vaccination and to a possible SARS-CoV-2 infection. In a short accompanying questionnaire, the professional ac
Sponsors
BG Klinikum Unfallkrankenhaus Berlin gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Employed at ukb / subsidiaries of ukb 2. Age> = 18 years 3. Able to give consent 4. Signed informed consent
Exclusion criteria
Exclusion criteria: 1. Not employed at ukb / subsidiaries of ukb 2. Age <18 years 3. Incapable of consent 4. No signed informed consent available
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No primary endpoint in the traditional sense due to the design of the study. Primary question: Determination of the relationship between the quantitative antibody response and the vaccination strategy. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary endpoint in the traditional sense due to the design of the study. Secondary question: Influence of the time interval after the second vaccination, age, gender, occupational group, previous infection and booster vaccination on the quantitative antibody response. Tertiary question: Development of the antibody response of employees who have previously tested seropositive. | — |
Countries
Germany
Contacts
Public ContactKristina Zappel
Zentrum für Klinische Forschung BG Klinikum Unfallkrankenhaus Berlin gGmbH
Outcome results
None listed